Base de dados : MEDLINE
Pesquisa : C04.588.443.665.710.650 [Categoria DeCS]
Referências encontradas : 13981 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 1399 ir para página                         

  1 / 13981 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29287881
[Au] Autor:Ünsaler S; Basaran B; Aslan I; Yilmazbayhan D
[Ad] Endereço:Department of Otolaryngology, Acibadem Altunizade Hospital, Üsküdar, Istanbul, 34662, Turkey. Electronic address: selinunsaler@gmail.com.
[Ti] Título:Endonasal endoscopic nasopharyngectomy for the treatment of nasopharyngeal papillary adenocarcinoma: Report of a rare case.
[So] Source:Int J Pediatr Otorhinolaryngol;104:51-53, 2018 Jan.
[Is] ISSN:1872-8464
[Cp] País de publicação:Ireland
[La] Idioma:eng
[Ab] Resumo:We report a case of low-grade nasopharyngeal papillary adenocarcinoma in a 9 year-old male that was diagnosed incidentally after an adenoidectomy procedure and treated with endonasal endoscopic nasopharyngectomy without any adjuvant therapy. The patient has been followed up for 3 years with no evidence of recurrence. We point out the importance of preoperative fiberoptic nasopharyngoscopy in the absence of longstanding symptoms in school-aged children and histopathologic examination of adenoidectomy specimens in the presence of atypical findings. We also suggest endonasal endoscopic resection in case of papillary adenocarcinoma.
[Mh] Termos MeSH primário: Adenocarcinoma Papilar/cirurgia
Carcinoma/cirurgia
Endoscopia/métodos
Neoplasias Nasofaríngeas/cirurgia
Faringectomia/métodos
[Mh] Termos MeSH secundário: Adenoidectomia
Criança
Seres Humanos
Masculino
Procedimentos Cirúrgicos Nasais/métodos
Nariz/patologia
Nariz/cirurgia
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180309
[Lr] Data última revisão:
180309
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171231
[St] Status:MEDLINE


  2 / 13981 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29480859
[Au] Autor:Hong YT; Hong KH
[Ad] Endereço:Department of Otolaryngology-HNS, Institute for Medical Science, Chonbuk National University, Chonbuk National University Hospital, Jeonju, South Korea.
[Ti] Título:Sequential occurrence of diffuse large B-cell lymphoma and carcinoma in the nasopharynx: A case report.
[So] Source:Medicine (Baltimore);97(2):e9595, 2018 Jan.
[Is] ISSN:1536-5964
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: The sequential occurrence of the 2 malignancies development of nasopharyngeal carcinoma (NPC) and lymphoma is extremely rare and their coexistence raises the question of a common etiologic factor. CLINICAL FINDINGS/CLINICAL CONCERNS: A 71-year-old previously healthy man presented with diffuse large B-cell lymphoma (BCL) followed by NPC almost 2 years later with Epstein-Barr virus (EBV) positive. DIAGNOSIS: Endoscopic examination characterized a fixed, hard and nontender mass in the nasopharynx and biopsies were done. INTERVENTION: A patient successfully underwent chemotherapy for lymphoma and chemoradiation for carcinoma sequentially. OUTCOMES: He was followed up every 3 months for 1 year with endoscopic and radiological examinations. The nasopharynx mass was completely resolved after chemoradiation therapy. CONCLUSION: The presentation with diffuse large B-cell lymphoma (BCL) and NPC in this patient was perhaps caused by dual EBV infection or a different oncogenic mechanism.
[Mh] Termos MeSH primário: Carcinoma/tratamento farmacológico
Carcinoma/radioterapia
Infecções por Vírus Epstein-Barr/complicações
Linfoma Difuso de Grandes Células B/tratamento farmacológico
Neoplasias Nasofaríngeas/tratamento farmacológico
Neoplasias Nasofaríngeas/radioterapia
Segunda Neoplasia Primária/tratamento farmacológico
Segunda Neoplasia Primária/radioterapia
[Mh] Termos MeSH secundário: Idoso
Carcinoma/patologia
Carcinoma/virologia
Seres Humanos
Linfoma Difuso de Grandes Células B/diagnóstico por imagem
Linfoma Difuso de Grandes Células B/patologia
Linfoma Difuso de Grandes Células B/virologia
Masculino
Neoplasias Nasofaríngeas/patologia
Neoplasias Nasofaríngeas/virologia
Segunda Neoplasia Primária/patologia
Segunda Neoplasia Primária/virologia
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180305
[Lr] Data última revisão:
180305
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:180227
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000009595


  3 / 13981 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29442000
[Au] Autor:Li YL; Zhao YG; Chen B; Li XF
[Ti] Título:MicroRNA-132 sensitizes nasopharyngeal carcinoma cells to cisplatin through regulation of forkhead box A1 protein.
[So] Source:Pharmazie;71(12):715-718, 2016 Dec 01.
[Is] ISSN:0031-7144
[Cp] País de publicação:Germany
[La] Idioma:eng
[Ab] Resumo:Chemoresistance in cancer is one of the major hindrances in cisplatin (DPP) treatment for nasopharyngeal carcinoma (NPC). The mechanism of such resistance remains unknown. Therefore, the present study aimed to clarify the mechanism of DDP resistance and attempted to reduce chemoresistance. Here, we found that miR-132, as a tumor suppressor, was poorly expressed in a cisplatin resistant CNE2 cell line (CNE2/DPP) accompanied with a decreased expression of miR-132 and an increased expression of FOXA1 compared with the parental cells CNE2. Exogenous overexpression of miR-132 in CNE2/DPP could sensitize their reaction to the treatment of cisplatin. In addition, FOXA1 knockdown in CNE2/DPP cells increased the chemosensitivity to DPP, suggesting the dependence of FOXA1 regulation in miR-132 activity. Moreover, miR-132 can restore cisplatin treatment response in cisplatin-resistant xenografts in vivo, while FOXA1 protein levels were decreased. In summary, our results provide novel mechanistic insights into the role of miR-132/FOXA1 signaling in the cisplatin resistance of NPC cells. Targeting of miR-132 is a potential therapeutic approach for NPC.
[Mh] Termos MeSH primário: Antineoplásicos/farmacologia
Carcinoma/tratamento farmacológico
Cisplatino/farmacologia
Fator 3-alfa Nuclear de Hepatócito/efeitos dos fármacos
Fator 3-alfa Nuclear de Hepatócito/metabolismo
MicroRNAs/farmacologia
Neoplasias Nasofaríngeas/tratamento farmacológico
[Mh] Termos MeSH secundário: Animais
Linhagem Celular Tumoral
Resistência a Medicamentos Antineoplásicos
Feminino
Técnicas de Silenciamento de Genes
Seres Humanos
Camundongos
Camundongos Nus
Transplante de Neoplasias
Interferência de RNA
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antineoplastic Agents); 0 (Hepatocyte Nuclear Factor 3-alpha); 0 (MIRN132 microRNA, mouse); 0 (MicroRNAs); Q20Q21Q62J (Cisplatin)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180227
[Lr] Data última revisão:
180227
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180215
[St] Status:MEDLINE
[do] DOI:10.1691/ph.2016.6764


  4 / 13981 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27775992
[Au] Autor:Ma WS; Ma JG; Xing LN
[Ad] Endereço:Department of Tumor Radiotherapy, the Second Affiliated Hospital of Harbin Medical University, Harbin, People's Republic of China.
[Ti] Título:Efficacy and safety of recombinant human adenovirus p53 combined with chemoradiotherapy in the treatment of recurrent nasopharyngeal carcinoma.
[So] Source:Anticancer Drugs;28(2):230-236, 2017 02.
[Is] ISSN:1473-5741
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:This study aims to explore the efficacy and safety of recombinant human adenovirus p53 (rAd-p53) combined with chemoradiotherapy (CRT) in the treatment of recurrent nasopharyngeal carcinoma (NPC). A total of 162 recurrent NPC patients were selected and divided randomly into the rAd-p53+CRT, CRT, and rAd-p53 groups. An electrochemical luminescence immune analyzer was used to detect serum levels of tumor markers (carcinoembryonic antigen, cancer antigen 199, and cancer antigen 153). Efficacy evaluation was in accordance with Response Evaluation Criteria in Solid Tumor. Toxicity evaluation was performed according to the WHO grading standard. A 3-year follow-up was performed. A Kaplan-Meier curve was drawn to calculate progression-free survival and the 3-year survival rate. The complete response rate and effective rate (complete response+partial response) of recurrent NPC patients in the rAd-p53+CRT group were higher than those in the CRT and rAd-p53groups. After treatment, compared with the CRT and rAd-p53 groups, the rAd-p53+CRT group had lower serum levels of carcinoembryonic antigen, cancer antigen 199, and cancer antigen 153. The incidences of leukopenia and oral mucositis in the rAd-p53+CRT group were lower than those in the CRT group, but no differences were found between the rAd-p53+CRT and rAd-p53 groups. The progression-free survival and 3-year survival rate of recurrent NPC patients in the rAd-p53+CRT group were higher than the than those in the CRT and rAd-p53 groups. Our study supports that rAd-p53 combined with CRT may provide better efficacy and lower toxicity than rAd-p53 or CRT alone for the treatment of recurrent NPC patients.
[Mh] Termos MeSH primário: Adenovírus Humanos/genética
Neoplasias Nasofaríngeas/terapia
Proteína Supressora de Tumor p53/genética
[Mh] Termos MeSH secundário: Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico
Biomarcadores Tumorais/sangue
Quimiorradioterapia
Cisplatino/administração & dosagem
Terapia Combinada
Feminino
Fluoruracila/administração & dosagem
Seres Humanos
Masculino
Meia-Idade
Neoplasias Nasofaríngeas/sangue
Neoplasias Nasofaríngeas/virologia
Recidiva Local de Neoplasia/sangue
Recidiva Local de Neoplasia/terapia
Recidiva Local de Neoplasia/virologia
[Pt] Tipo de publicação:JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Biomarkers, Tumor); 0 (TP53 protein, human); 0 (Tumor Suppressor Protein p53); Q20Q21Q62J (Cisplatin); U3P01618RT (Fluorouracil)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:180227
[Lr] Data última revisão:
180227
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161025
[St] Status:MEDLINE
[do] DOI:10.1097/CAD.0000000000000448


  5 / 13981 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29329342
[Au] Autor:Ahmad M; Suhaimi SN; Chu TL; Abdul Aziz N; Mohd Kornain NK; Samiulla DS; Lo KW; Ng CH; Khoo AS
[Ad] Endereço:Molecular Pathology Unit, Cancer Research Centre, Institute for Medical Research, Kuala Lumpur, Malaysia.
[Ti] Título:Ternary copper(II) complex: NCI60 screening, toxicity studies, and evaluation of efficacy in xenograft models of nasopharyngeal carcinoma.
[So] Source:PLoS One;13(1):e0191295, 2018.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Copper(II) ternary complex, [Cu(phen)(C-dmg)(H2O)]NO3 was evaluated against a panel of cell lines, tested for in vivo efficacy in nasopharyngeal carcinoma xenograft models as well as for toxicity in NOD scid gamma mice. The Cu(II) complex displayed broad spectrum cytotoxicity against multiple cancer types, including lung, colon, central nervous system, melanoma, ovarian, and prostate cancer cell lines in the NCI-60 panel. The Cu(II) complex did not cause significant induction of cytochrome P450 (CYP) 3A and 1A enzymes but moderately inhibited CYP isoforms 1A2, 2C9, 2C19, 2D6, 2B6, 2C8 and 3A4. The complex significantly inhibited tumor growth in nasopharyngeal carcinoma xenograft bearing mice models at doses which were well tolerated without causing significant or permanent toxic side effects. However, higher doses which resulted in better inhibition of tumor growth also resulted in toxicity.
[Mh] Termos MeSH primário: Antineoplásicos/química
Antineoplásicos/farmacologia
Carcinoma/tratamento farmacológico
Cobre/química
Neoplasias Nasofaríngeas/tratamento farmacológico
Compostos Organometálicos/química
Compostos Organometálicos/farmacologia
Ensaios Antitumorais Modelo de Xenoenxerto
[Mh] Termos MeSH secundário: Animais
Antineoplásicos/toxicidade
Carcinoma/patologia
Linhagem Celular Tumoral
Inibidores das Enzimas do Citocromo P-450/química
Inibidores das Enzimas do Citocromo P-450/farmacologia
Inibidores das Enzimas do Citocromo P-450/toxicidade
Sistema Enzimático do Citocromo P-450/biossíntese
Sistema Enzimático do Citocromo P-450/metabolismo
Relação Dose-Resposta a Droga
Indução Enzimática/efeitos dos fármacos
Feminino
Hepatócitos/efeitos dos fármacos
Camundongos
Neoplasias Nasofaríngeas/patologia
Compostos Organometálicos/toxicidade
Ratos
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Antineoplastic Agents); 0 (Cytochrome P-450 Enzyme Inhibitors); 0 (Organometallic Compounds); 789U1901C5 (Copper); 9035-51-2 (Cytochrome P-450 Enzyme System)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180226
[Lr] Data última revisão:
180226
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180113
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0191295


  6 / 13981 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28455969
[Au] Autor:Wang MH; Zhou XM; Zhang MY; Shi L; Xiao RW; Zeng LS; Yang XZ; Zheng XFS; Wang HY; Mai SJ
[Ad] Endereço:State Key Laboratory of Oncology in South China, Guangzhou, 510060, China.
[Ti] Título:BMP2 promotes proliferation and invasion of nasopharyngeal carcinoma cells via mTORC1 pathway.
[So] Source:Aging (Albany NY);9(4):1326-1340, 2017 Apr.
[Is] ISSN:1945-4589
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Bone morphogenetic protein-2 (BMP2) is a secreted protein that highly expressed in a variety of cancers and contributes to cell proliferation, migration, invasiveness, mobility, metastasis and EMT. However, its clinical significance and biological function in nasopharyngeal carcinoma (NPC) remain unknown up to now. Up-regulation of BMP2 was first observed in NPC cell lines by a genome-wide transcriptome analysis in our previous study. In this study, BMP2 mRNA was detected by qRT-PCR and data showed that it was upregulated in NPC compared with non-cancerous nasopharynx samples. Immunohistochemistry (IHC) analysis in NPC specimens revealed that high BMP2 expression was significantly associated with clinical stage, distant metastasis and shorter survival of NPC patients. Moreover, overexpression of BMP2 in NPC cells promoted cell proliferation, migration, invasiveness and epithelial-mesenchymal transition (EMT). Mechanistically, BMP2 overexpression increase phosphorylated protein level of mTOR, S6K and 4EBP1. Correspondingly, mTORC1 inhibitor rapamycin blocked the effect of BMP2 on NPC cell proliferation and invasion. In conclusion, our results suggest that BMP2 overexpression in NPC enhances proliferation, invasion and EMT of tumor cells through the mTORC1 signaling pathway.
[Mh] Termos MeSH primário: Proteína Morfogenética Óssea 2/farmacologia
Proliferação Celular/efeitos dos fármacos
Alvo Mecanístico do Complexo 1 de Rapamicina/efeitos dos fármacos
Neoplasias Nasofaríngeas/patologia
Invasividade Neoplásica/patologia
[Mh] Termos MeSH secundário: Linhagem Celular Tumoral
Movimento Celular/efeitos dos fármacos
Transição Epitelial-Mesenquimal/efeitos dos fármacos
Regulação Neoplásica da Expressão Gênica
Estudo de Associação Genômica Ampla
Seres Humanos
Alvo Mecanístico do Complexo 1 de Rapamicina/genética
Neoplasias Nasofaríngeas/genética
Metástase Neoplásica
RNA Mensageiro/biossíntese
RNA Mensageiro/genética
Receptores da Colecistocinina/biossíntese
Transdução de Sinais/efeitos dos fármacos
Transcriptoma/genética
Regulação para Cima/efeitos dos fármacos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Bone Morphogenetic Protein 2); 0 (RNA, Messenger); 0 (Receptors, Cholecystokinin); EC 2.7.11.1 (Mechanistic Target of Rapamycin Complex 1)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180216
[Lr] Data última revisão:
180216
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170430
[St] Status:MEDLINE
[do] DOI:10.18632/aging.101230


  7 / 13981 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29365376
[Au] Autor:Fang Y; Xu C; Li DW; Wang ZL; Zhang L; Wu P; Wang ZZ; Du H; Li WF; Liao ZS
[Ad] Endereço:First Clinical Institute, Wenzhou Medical University, Wenzhou 325000, China.
[Ti] Título:[Tumor-secreted vascular endothelial growth factor A increases the pulmonary metastasis from nasopharyngeal carcinoma].
[So] Source:Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi;53(1):27-33, 2018 Jan 07.
[Is] ISSN:1673-0860
[Cp] País de publicação:China
[La] Idioma:chi
[Ab] Resumo:Vascular endothelial growth factor A (VEGFA) was investigated as the key protein which might promote the specific metastasis progress of nasopharyngeal carcinoma. Sixteen specimens of pulmonary metastasis carcinoma and counterparts in primary nasopharyngeal carcinoma tissue were collected from patients. The expression of VEGFA through immunohistochemistry was investigated.VEGFA was knocked down by siRNA in two cell lines of nasopharyngeal carcinoma (CNE-1 and 5-8F), MTT and Transwell test were used to explore the role of VEGFA in praxiology. Then shRNA was used to cultivate the stable CNE-1 cell line with down-regulated-expression of VEGFA. The nude mice models were built through tail vein injection of specific nasopharyngeal carcinoma cells, and lungs were collected to perform further metastasis analysis. Previous genetic studies showed that VEGFA had higher expression in metastasis tissue, and the result was validated in the present study using immunohistochemistry. The percentage of positive cells was 84.8% in pulmonary metastasis group, 51.5% in primary tissue group ( =8.639, <0.05), average optical density was 0.154 in pulmonary metastasis group, 0.061 in primary tissue group ( =18.791, <0.05). Low expression of VEGFA inhibited cell viability of optical density value of CNE-1 in siRNA gourp was 0.715, 0.902 in control group ( =7.274, <0.05); 5-8F in siRNA group was 0.715, 0.935 in control group ( =7.751, <0.05). Number counting suppressed migration of CNE-1 in siRNA group was 52 per high-power lens, 124 per high-power lens in control group ( =29.380, <0.05), 5-8F in siRNA group was 65 per high-power lens, 155 per high-power lens in control group ( =18.181, <0.05). Number counting invasion of CNE-1 in siRNA gourp was 38 per high-power lens, 86 per high-power lens in control group ( =27.665, <0.05), 5-8F in siRNA group was 52 per high-power lens, 116 per high-power lens in control group ( =40.972, <0.05) in vitro. Furthermore, knock-down of VEGFA in nasopharyngeal carcinoma reduced the pulmonary metastasis . Number counting of tumor volumes in shRNA group was 2.4, and 11.0 in control group ( =6.143, <0.05); average optical density of immunohistochemistry in shRNA group was 0.033, and 0.176 in control group ( =15.734, <0.05). Results above reveal the overexpression of VEGFA in nasopharyngeal carcinoma can facilitate the pulmonary metastasis. Targeting VEGFA may provide a new biomarker of clinical study.
[Mh] Termos MeSH primário: Carcinoma/secundário
Carcinoma/secreção
Neoplasias Pulmonares/secundário
Neoplasias Nasofaríngeas/patologia
Neoplasias Nasofaríngeas/secreção
Fator A de Crescimento do Endotélio Vascular/secreção
[Mh] Termos MeSH secundário: Animais
Regulação para Baixo
Técnicas de Inativação de Genes
Seres Humanos
Imuno-Histoquímica
Camundongos
Camundongos Nus
RNA Interferente Pequeno
Fator A de Crescimento do Endotélio Vascular/genética
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (RNA, Small Interfering); 0 (VEGFA protein, human); 0 (Vascular Endothelial Growth Factor A)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180215
[Lr] Data última revisão:
180215
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180125
[St] Status:MEDLINE
[do] DOI:10.3760/cma.j.issn.1673-0860.2018.01.006


  8 / 13981 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29247573
[Au] Autor:Yoshizaki T; Kondo S; Endo K; Nakanishi Y; Aga M; Kobayashi E; Hirai N; Sugimoto H; Hatano M; Ueno T; Ishikawa K; Wakisaka N
[Ad] Endereço:Department of Otolaryngology - Head and Neck Surgery, Graduate School of Medicine, Kanazawa University, Kanazawa, Japan.
[Ti] Título:Modulation of the tumor microenvironment by Epstein-Barr virus latent membrane protein 1 in nasopharyngeal carcinoma.
[So] Source:Cancer Sci;109(2):272-278, 2018 Feb.
[Is] ISSN:1349-7006
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Latent membrane protein 1 (LMP1) is a primary oncogene encoded by the Epstein-Barr virus, and various portions of LMP1 are detected in nasopharyngeal carcinoma (NPC) tumor cells. LMP1 has been extensively studied since the discovery of its transforming property in 1985. LMP1 promotes cancer cell growth during NPC development and facilitates the interaction of cancer cells with surrounding stromal cells for invasion, angiogenesis, and immune modulation. LMP1 is detected in 100% of pre-invasive NPC tumors and in approximately 50% of advanced NPC tumors. Moreover, a small population of LMP1-expressing cells in advanced NPC tumor tissue is proposed to orchestrate NPC tumor tissue maintenance and development through cancer stem cells and progenitor cells. Recent studies suggest that LMP1 activity shifts according to tumor development stage, but it still has a pivotal role during all stages of NPC development.
[Mh] Termos MeSH primário: Carcinoma/patologia
Infecções por Vírus Epstein-Barr/metabolismo
Neoplasias Nasofaríngeas/patologia
Proteínas da Matriz Viral/metabolismo
[Mh] Termos MeSH secundário: Carcinoma/metabolismo
Carcinoma/virologia
Proliferação Celular
Herpesvirus Humano 4/metabolismo
Seres Humanos
Neoplasias Nasofaríngeas/metabolismo
Neoplasias Nasofaríngeas/virologia
Estadiamento de Neoplasias
Células-Tronco Neoplásicas/metabolismo
Microambiente Tumoral
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (EBV-associated membrane antigen, Epstein-Barr virus); 0 (Viral Matrix Proteins)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180216
[Lr] Data última revisão:
180216
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171217
[St] Status:MEDLINE
[do] DOI:10.1111/cas.13473


  9 / 13981 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29384905
[Au] Autor:Liu JQ; Mai WY; Wang SB; Lou YJ; Yan SX; Jin J; Xu WL
[Ad] Endereço:Department of Radiation Oncology, The First Affiliated Hospital, College of Medicine, Zhejiang University.
[Ti] Título:Central nervous system leukemia in a patient with concurrent nasopharyngeal carcinoma and acute myeloid leukaemia: A case report.
[So] Source:Medicine (Baltimore);96(52):e9199, 2017 Dec.
[Is] ISSN:1536-5964
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:RATIONALE: Concurrent case of nasopharyngeal carcinoma (NPC) and acute myeloid leukemia (AML) has not been reported. Here, we report a case of NPC, who was concurrently suffered from AML one mother after the NPC diagnosis. PATIENT CONCERNS: The patient was a 45-year-old male who presented with a mass on his right side neck. DIAGNOSES: The patient was diagnosed with Epstein-Barr virus negative type-2 non-keratinizing carcinoma with clivus involvement and unilateral metastasis to the cervical lymph node. INTERVENTIONS: He was treated with one cycle of cisplatin and 69.76 Gy of concurrent external-beam radiation. OUTCOMES: Three months after completion of chemo-radiotherapy, the patient was diagnosed as acute myeloid leukemia, which achieved complete remission after one course induction chemotherapy. Two months later, however, the patient was diagnosed as central nervous system leukemia. He ultimately died of relapsed leukemia. The overall survival of the patient was 10 months. LESSONS: The co-occurrence of NPC and AML is rare and prognosis is poor. Radiotherapy in NPC can disrupt the blood-brain barrier, which may contribute to the pathogenesis of central nervous system leukemia. Early alert and prevention of central nervous system leukemia following radiotherapy in NPC patient is recommended.
[Mh] Termos MeSH primário: Carcinoma/complicações
Carcinoma/diagnóstico
Neoplasias do Sistema Nervoso Central/complicações
Neoplasias do Sistema Nervoso Central/diagnóstico
Leucemia Mieloide Aguda/complicações
Leucemia Mieloide Aguda/diagnóstico
Neoplasias Nasofaríngeas/complicações
Neoplasias Nasofaríngeas/diagnóstico
[Mh] Termos MeSH secundário: Carcinoma/terapia
Neoplasias do Sistema Nervoso Central/terapia
Seres Humanos
Leucemia Mieloide Aguda/terapia
Masculino
Meia-Idade
Neoplasias Nasofaríngeas/terapia
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180209
[Lr] Data última revisão:
180209
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:180201
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000009199


  10 / 13981 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29381996
[Au] Autor:Zhang WL; Ma S; Havrilla L; Cai L; Yu CQ; Shen S; Xu HT; Wang L; Yu JH; Lin XY; Wang E; Yang LH
[Ad] Endereço:Department of Pathology, First Affiliated Hospital and College of Basic Medical Sciences, China Medical University.
[Ti] Título:Primary thyroid-like low-grade nasopharyngeal papillary adenocarcinoma: A case report and literature review.
[So] Source:Medicine (Baltimore);96(47):e8851, 2017 Nov.
[Is] ISSN:1536-5964
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:RATIONALE: Primary thyroid-like low-grade nasopharyngeal papillary adenocarcinoma (TL-LGNPPA) is an extremely rare malignant nasopharyngeal tumor with features resembling papillary thyroid carcinoma including nuclear positive expression of thyroid transcription factor-1 (TTF-1). PATIENT CONCERNS: A 64-year-old male presented with nasal bleeding and a foreign body sensation of the nasopharynx. Laryngoscopy revealed a 2.0-cm broad-based mass with a smooth surface on the posterior wall of the nasopharynx. A biopsy was obtained. DIAGNOSES: Histopathologic examination demonstrated tumor cells arranged in both papillary and glandular architecture. The tumor cells express nuclear immunoreactivity for TTF-1. The diagnosis of TL-LGNPPA was made. INTERVENTIONS: After the patient was diagnosed with TL-LGNPPA, he underwent complete surgical resection. OUTCOMES: There was no recurrence or evidence of metastatic disease at the 12-month follow-up. LESSONS: TL-LGNPPA is easy to misdiagnose as metastatic papillary thyroid carcinoma or other relative primary adenocarcinomas. It is important to have a broad differential diagnosis and know the key features of each entity because the prognosis and clinical treatment of each may differ.
[Mh] Termos MeSH primário: Adenocarcinoma Papilar/patologia
Neoplasias Nasofaríngeas/patologia
[Mh] Termos MeSH secundário: Adenocarcinoma Papilar/diagnóstico
Carcinoma Papilar/diagnóstico
Diagnóstico Diferencial
Seres Humanos
Imuno-Histoquímica
Masculino
Meia-Idade
Neoplasias Nasofaríngeas/diagnóstico
Nasofaringe/patologia
Neoplasias da Glândula Tireoide/diagnóstico
Fator Nuclear 1 de Tireoide/metabolismo
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Thyroid Nuclear Factor 1)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180209
[Lr] Data última revisão:
180209
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:180201
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000008851



página 1 de 1399 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde